info@example.com

+1 66589 14556

Genetic Testing in Prostate Cancer: BRCA and Hereditary Risk

Genetic Testing in Prostate Cancer: BRCA and Hereditary Risk

📖 5 min read Written and medically reviewed by Dr. Alhad Naragude, MBBS, MS, DrNB Urology Last updated: September 6, 2026

Genetic testing in prostate cancer can mean two different tests: germline testing looks for inherited variants present in all cells, while tumour (somatic) testing looks for changes within the cancer itself. BRCA2 is the most important hereditary prostate-cancer gene, although BRCA1, ATM, PALB2, CHEK2, mismatch-repair genes and others can be relevant. Results can affect treatment—such as eligibility for PARP inhibitors in advanced disease—and can identify relatives who may benefit from genetic counselling and earlier cancer screening. Testing is most strongly considered in metastatic, high-risk, intraductal/cribriform or strongly familial disease.

Germline versus tumour testing

  • Germline test: usually blood/saliva; asks whether a cancer-risk variant was inherited and can be passed to children
  • Somatic/tumour test: uses tumour tissue or circulating DNA; finds treatment-relevant changes that may or may not be inherited

Why BRCA2 matters

Men with inherited BRCA2 pathogenic variants have a higher lifetime risk of prostate cancer and are more likely to develop aggressive disease. A positive result has implications beyond prostate cancer, including risks for breast, pancreatic and other cancers within the family.

Who should discuss genetic testing?

Indications vary by guideline and resources, but commonly include metastatic prostate cancer, high/very-high-risk disease, certain adverse pathological patterns, a strong family history of prostate/breast/ovarian/pancreatic cancer, Ashkenazi Jewish ancestry in some pathways, or a known familial pathogenic variant.

How results can change treatment

Homologous recombination-repair alterations—especially BRCA1/2—can predict benefit from PARP-inhibitor strategies in selected advanced prostate cancers. Mismatch-repair deficiency or microsatellite instability can support use of immune checkpoint therapy in appropriate metastatic settings.

Why genetic counselling matters

A “variant of uncertain significance” is not the same as a harmful mutation and should not drive surgery or family testing on its own. Pathogenic germline results require careful explanation of inheritance, cascade testing and implications for male and female relatives.

A tumour mutation and an inherited mutation are different findings

Tumour sequencing may find a BRCA2 or other DNA-repair alteration that arose only in the cancer. Germline testing asks whether the variant is present throughout the body and can be inherited by relatives. A tumour result with hereditary implications often needs confirmatory germline testing and counselling.

BRCA2 matters more than a vague “family history of cancer”

Hereditary prostate-cancer assessment looks for patterns such as early or multiple prostate cancers, male or female breast cancer, ovarian cancer, pancreatic cancer and known pathogenic variants across maternal and paternal relatives. A precise three-generation history is more useful than simply saying cancer “runs in the family.”

A VUS should not drive irreversible decisions

A variant of uncertain significance means the laboratory cannot classify the change as harmful or benign. It should not be treated as a positive hereditary-cancer result and should not by itself trigger prophylactic surgery or predictive testing of relatives. Reclassification may occur as evidence accumulates.

There are two different genetic questions

Germline testing asks whether an inherited alteration such as BRCA1/2 is present in every cell and may affect relatives. Tumour or somatic testing looks for changes within the cancer that may guide treatment even when they are not inherited. A positive result can influence PARP-inhibitor eligibility in advanced disease and can trigger cascade testing for family members. Pre-test counselling is useful because a variant of uncertain significance is not the same as a pathogenic mutation.

When to seek earlier medical review

Genetic results do not usually create an emergency. Arrange genetics/oncology review for a pathogenic germline result, a confusing variant of uncertain significance, or when a family member’s cancer history suggests broader hereditary assessment.

Emergency warning signs

  • Inability to pass urine
  • New severe back pain with leg weakness, numbness or loss of bladder/bowel control
  • Severe bleeding after biopsy or inability to pass urine
  • Fever or chills after prostate biopsy

What to bring to your consultation

  • Prostate pathology/stage
  • Family cancer history across both sides of family
  • Any previous tumour-genomic report
  • Prior genetic test result if already done

Questions to ask your doctor

  • Do I need germline testing, tumour testing or both?
  • Would a positive result alter my treatment now?
  • Which relatives should receive genetic counselling if a pathogenic germline variant is found?

FAQs

If I have BRCA, did I inherit it from my mother?

A germline BRCA variant can be inherited from either mother or father.

Does a BRCA mutation mean my children definitely have it?

For an autosomal-dominant BRCA pathogenic variant, each biological child has a 50% chance of inheriting it.

Should every man with prostate cancer get genetic testing?

Not necessarily. Testing is targeted to clinical and family-history criteria, although recommendations are expanding.

What if tumour testing finds BRCA2?

It may be somatic or germline. Confirmatory germline testing and genetic counselling are often appropriate because the family implications are different.

Related reading

References

Note: This information is for educational purposes only and is not a substitute for medical advice. Please consult your doctor for any symptoms.